Literature DB >> 12074699

Enhancement of the immune response generated against hepatitis C virus envelope proteins after DNA vaccination with polyprotein-encoding plasmids.

Santiago Dueñas-Carrera1, Liz Alvarez-Lajonchere, Julio César Alvarez-Obregón, Anna Pérez, Nelson Acosta-Rivero, Dania Marcia Vázquez, Gillian Martínez, Ariel Viña, Dagmara Pichardo, Juan Morales.   

Abstract

Plasmids expressing variants of the hepatitis C virus (HCV) core, E1 and E2 proteins individually or as polyproteins were administered to BALB/c mice. All plasmids induced a detectable and specific antibody response. Antibody titres against core, E1 and E2 proteins, 19 weeks after primary immunization, ranged from 1:50 to 1:4500 depending on the inoculated plasmid and the HCV antigen evaluated. Constructs expressing HCV envelope proteins as polyprotein variants including the core amino acid region induced statistically stronger antibody responses than plasmids encoding individual E1 and E2 proteins. Particularly, the pIDKE2 plasmid, expressing the first 650 amino acids in the viral polyprotein, induced a potent and multispecific antibody and lymphoproliferative response against HCV core, E1 and E2 proteins. Anti-E2 antibodies generated by pIDKE2 immunization were cross-reactive to hypervariable region-1 peptides from different genotypes. Immunization with the pIDKE2 also generated a positive cellular immune response against the core antigen, determined by interferon-gamma enzyme-linked immunospot (ELISPOT) assay, and induced detectable levels of interferon-gamma but not interleukin-4 in vaccinated mice. The detection of both antibody and cytotoxic T-lymphocyte responses, potentially targeted to circulating or cell-infecting virions respectively, in mice vaccinated with the pIDKE2 plasmid is very attractive for the effective eradication of HCV infection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12074699     DOI: 10.1042/ba20010089

Source DB:  PubMed          Journal:  Biotechnol Appl Biochem        ISSN: 0885-4513            Impact factor:   2.431


  5 in total

Review 1.  Synthetic DNA vaccine strategies against persistent viral infections.

Authors:  Daniel O Villarreal; Kendra T Talbott; Daniel K Choo; Devon J Shedlock; David B Weiner
Journal:  Expert Rev Vaccines       Date:  2013-05       Impact factor: 5.217

2.  Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice.

Authors:  Santa Olivera; Angel Perez; Viviana Falcon; Dioslaida Urquiza; Dagmara Pichardo; Gillian Martinez-Donato
Journal:  Arch Virol       Date:  2020-02-03       Impact factor: 2.574

3.  HCV-specific immune responses induced by CIGB-230 in combination with IFN-α plus ribavirin.

Authors:  Yalena Amador-Cañizares; Gillian Martínez-Donato; Liz Alvarez-Lajonchere; Claudia Vasallo; Mariacarla Dausá; Daylen Aguilar-Noriega; Carmen Valenzuela; Ivette Raíces; Jean Dubuisson; Czeslaw Wychowski; Zurina Cinza-Estévez; Marlén Castellanos; Magdalys Núñez; Anny Armas; Yaimé González; Ismariley Revé; Ivis Guerra; Angel Pérez Aguiar; Santiago Dueñas-Carrera
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

4.  Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients.

Authors:  Daniel Palenzuela Gardón; Isabel Alicia Guillen; Julio R Fernández; Hamlet Camacho; Zurina Cinza Estevez; Santiago Dueñas; Liz Alvares-Lajonchere; Yalena Amador; Gillian Martinez-Donato; Junsong Han; Zhiming Zhang; Xiaona Zhang; Yang Gao; Juan Roca Campaña; Lidia I Novoa
Journal:  J Biomol Tech       Date:  2016-12-16

5.  Hepatitis C virus DNA vaccines: a systematic review.

Authors:  Ali Shayeghpour; Roya Kianfar; Parastoo Hosseini; Mehdi Ajorloo; Sepehr Aghajanian; Mojtaba Hedayat Yaghoobi; Tayebeh Hashempour; Sayed-Hamidreza Mozhgani
Journal:  Virol J       Date:  2021-12-13       Impact factor: 4.099

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.